Prostate Cancer Breakthrough
Men in England with low- and intermediate-risk prostate cancer will now have access to a revolutionary targeted radiotherapy, known as SABR, which reduces treatment sessions from 20 to just five π. This form of radiotherapy will target the disease more effectively than standard radiotherapy and help reduce side-effects π₯. What does this new development mean for the future of cancer treatment and patient care?
Read More














